CA2365296A1 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
CA2365296A1
CA2365296A1 CA002365296A CA2365296A CA2365296A1 CA 2365296 A1 CA2365296 A1 CA 2365296A1 CA 002365296 A CA002365296 A CA 002365296A CA 2365296 A CA2365296 A CA 2365296A CA 2365296 A1 CA2365296 A1 CA 2365296A1
Authority
CA
Canada
Prior art keywords
polysaccharide
protein
mpl
streptococcus pneumoniae
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002365296A
Other languages
English (en)
French (fr)
Inventor
Pierre Michel Desmons
Jan Poolman
Craig Antony Joseph Laferriere
Carine Capiau
Jean-Paul Prieels
Marguerite Deschamps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Individual filed Critical Individual
Publication of CA2365296A1 publication Critical patent/CA2365296A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002365296A 1999-03-19 2000-03-17 Vaccine Abandoned CA2365296A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB9906437.0 1999-03-19
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GB9909077.1 1999-04-20
GB9909466.6 1999-04-23
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GB9916677.9 1999-07-15
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002465 WO2000056358A2 (en) 1999-03-19 2000-03-17 Vaccine against streptococcus pneumoniae capsular polysaccharides

Publications (1)

Publication Number Publication Date
CA2365296A1 true CA2365296A1 (en) 2000-09-28

Family

ID=27451884

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002365296A Abandoned CA2365296A1 (en) 1999-03-19 2000-03-17 Vaccine
CA2366314A Expired - Lifetime CA2366314C (en) 1999-03-19 2000-03-17 Protein d from haemophilus influenzae as a carrier protein in combination vaccines
CA002366152A Abandoned CA2366152A1 (en) 1999-03-19 2000-03-17 Streptococcus pneumoniae vaccine

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2366314A Expired - Lifetime CA2366314C (en) 1999-03-19 2000-03-17 Protein d from haemophilus influenzae as a carrier protein in combination vaccines
CA002366152A Abandoned CA2366152A1 (en) 1999-03-19 2000-03-17 Streptococcus pneumoniae vaccine

Country Status (32)

Country Link
US (8) US20030147922A1 (OSRAM)
EP (6) EP1880735A3 (OSRAM)
JP (4) JP2002540074A (OSRAM)
KR (3) KR20020000785A (OSRAM)
CN (3) CN1192798C (OSRAM)
AR (3) AR022963A1 (OSRAM)
AT (3) ATE346608T1 (OSRAM)
AU (3) AU750788B2 (OSRAM)
BE (1) BE1025464I2 (OSRAM)
BR (4) BRPI0009163B8 (OSRAM)
CA (3) CA2365296A1 (OSRAM)
CY (3) CY1107561T1 (OSRAM)
CZ (3) CZ20013378A3 (OSRAM)
DE (4) DE60032120T2 (OSRAM)
DK (2) DK1163000T3 (OSRAM)
ES (3) ES2275499T3 (OSRAM)
FR (1) FR10C0008I2 (OSRAM)
HK (3) HK1043728B (OSRAM)
HU (4) HUP0200664A2 (OSRAM)
IL (5) IL145043A0 (OSRAM)
LU (1) LU91652I2 (OSRAM)
MX (1) MXPA01009452A (OSRAM)
MY (2) MY125387A (OSRAM)
NL (1) NL300415I1 (OSRAM)
NO (4) NO330532B1 (OSRAM)
NZ (3) NZ513841A (OSRAM)
PL (3) PL355178A1 (OSRAM)
PT (2) PT1163000E (OSRAM)
SI (2) SI1162999T1 (OSRAM)
TR (3) TR200102739T2 (OSRAM)
TW (3) TWI235064B (OSRAM)
WO (3) WO2000056360A2 (OSRAM)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
AU1463097A (en) 1996-01-04 1997-08-01 Rican Limited Helicobacter pylori bacterioferritin
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
MY125387A (en) * 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
JP2005504718A (ja) 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP4662537B2 (ja) * 2002-05-14 2011-03-30 カイロン ソチエタ ア レスポンサビリタ リミタータ 細菌性髄膜炎に関する粘膜組合せワクチン
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8663656B2 (en) 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CN102174533A (zh) * 2002-10-15 2011-09-07 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
JP5102487B2 (ja) 2003-03-07 2012-12-19 ワイス・ホールディングズ・コーポレイション 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体
WO2004081515A2 (en) * 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
PT1631264E (pt) 2003-06-02 2009-11-03 Novartis Vaccines & Diagnostic Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
HUE033196T2 (en) 2005-01-27 2017-11-28 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1858920B1 (en) 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
MX291624B (es) 2005-02-18 2011-11-04 Novartis Vaccines & Diagnostic Inmunogenos de escherichia coli uropatogenica.
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102017842B1 (ko) 2005-04-08 2019-09-03 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0610297A2 (pt) 2005-04-18 2010-06-08 Novartis Vaccines & Diagnostic expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina
JP2008543907A (ja) * 2005-06-27 2008-12-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA2621023C (en) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EA014107B1 (ru) * 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EA015561B1 (ru) * 2006-01-17 2011-08-30 Арне Форсгрен НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE)
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
EP3006041B1 (en) * 2006-03-17 2017-11-29 The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
EA020459B1 (ru) * 2006-03-30 2014-11-28 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
JO3418B1 (ar) * 2006-03-30 2019-10-20 Glaxosmithkline Biologicals Sa عملية اقتران خاصة ب pnag وبروتين حامل
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US20100015168A1 (en) * 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CN102648979B (zh) * 2006-10-10 2014-05-14 惠氏公司 肺炎链球菌3型多糖的纯化
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0813644B8 (pt) * 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
RU2471497C2 (ru) 2007-09-12 2013-01-10 Новартис Аг Мутантные антигены gas57 и антитела против gas57
DK2200642T3 (da) 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
RU2498994C2 (ru) 2007-12-21 2013-11-20 Новартис Аг Мутантные формы стрептолизина о
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
MX351810B (es) 2008-07-21 2017-10-27 Brigham & Womens Hospital Inc Metodos y composiciones que se relacionan con oligosacaridos sinteticos de beta-1, 6 glucosamina.
WO2010049806A1 (en) 2008-10-27 2010-05-06 Novartis Ag Purification method
WO2010067286A2 (en) 2008-12-09 2010-06-17 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2748788C (en) 2009-01-05 2021-02-09 Epitogenesis Inc. The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
KR20120049900A (ko) 2009-07-30 2012-05-17 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
KR101660578B1 (ko) * 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
BR122019005883A8 (pt) 2009-10-30 2022-10-04 Novartis Ag Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SG10201506160VA (en) * 2009-12-17 2015-09-29 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
CA2785585A1 (en) 2009-12-22 2011-06-30 Celldex Therapeutics, Inc. Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011126863A1 (en) 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127302A2 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2011146910A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
US9095567B2 (en) * 2010-06-04 2015-08-04 Wyeth Llc Vaccine formulations
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
ES2686875T3 (es) 2011-05-06 2018-10-22 Aparin, Petr Gennadievich Exopolisacárido de la bacteria Shigella sonnei, método para producirlo, vacuna y composición farmacéutica que lo contienen
CN107837394A (zh) 2011-06-24 2018-03-27 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
JP6088507B2 (ja) 2011-07-08 2017-03-01 ノバルティス アーゲー チロシンライゲーションの方法
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
MX2014006630A (es) 2011-12-08 2014-07-09 Novartis Ag Vacuna a base toxina clostridium difficile.
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN104321078A (zh) 2012-04-26 2015-01-28 诺华股份有限公司 抗原和抗原组合
KR20200075023A (ko) 2012-05-04 2020-06-25 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
KR20150073160A (ko) 2012-10-03 2015-06-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
BR112015008040A2 (pt) 2012-10-12 2017-07-04 Glaxosmithkline Biologicals Sa composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina
AU2013333975A1 (en) * 2012-10-17 2015-05-07 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
JP2016520077A (ja) 2013-05-15 2016-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ Ｅ１ｅ２ｈｃｖワクチン及び使用方法
CN103386126B (zh) * 2013-06-25 2015-06-17 北京科兴生物制品有限公司 一种含肠道病毒抗原的多价免疫原性组合物
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
PE20212335A1 (es) 2014-01-21 2021-12-16 Pfizer Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
EA034954B1 (ru) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北京天成新脉生物技术有限公司 脑膜炎球菌荚膜多糖单克隆抗体及其应用
CN106715464B (zh) 2014-07-23 2021-03-16 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
BR112017013891B1 (pt) 2015-01-15 2024-01-30 Pfizer Inc Composições imunogênicas para uso em vacinas pneumocócicas
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
JP2018522885A (ja) 2015-07-07 2018-08-16 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩｇＥ介在性疾患の処置および予防のためのワクチン
KR102800419B1 (ko) 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
EP3341017B1 (en) 2015-08-25 2024-10-16 Babita Agrawal Immunomodulatory compositions comprising caulobacter crescentus and use thereof
WO2017060857A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CU20210061A7 (es) 2015-12-04 2022-02-04 Dana Farber Cancer Inst Inc Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
DK3405212T3 (da) 2016-01-19 2020-08-24 Pfizer Cancervacciner
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
WO2018027123A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11241489B2 (en) 2016-08-05 2022-02-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
AU2017339577B2 (en) 2016-10-07 2021-12-02 Enterome S.A. Immunogenic compounds for cancer therapy
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
SI3570879T1 (sl) 2017-01-20 2022-06-30 Pfizer Inc. Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
WO2018169303A1 (ko) * 2017-03-15 2018-09-20 주식회사 엘지화학 다가 폐렴구균 백신 조성물
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2018280272C1 (en) 2017-06-10 2021-05-06 Inventprise, Inc. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
JP2020530478A (ja) 2017-08-14 2020-10-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫応答を強化する方法
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
KR102686858B1 (ko) 2017-12-06 2024-07-19 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
WO2019152925A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215212B2 (en) 2018-02-05 2025-05-15 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
DK3773689T5 (da) 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
WO2019203599A1 (ko) 2018-04-18 2019-10-24 에스케이바이오사이언스 주식회사 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
JP7446279B2 (ja) 2018-07-19 2024-03-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乾燥多糖を調製するための方法
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
CN113453708B (zh) 2018-12-19 2025-02-21 默沙东有限责任公司 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法
CN113646438A (zh) 2019-01-11 2021-11-12 西北大学 在原核生物细胞裂解物中合成生物缀合物疫苗
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
EP3965826A1 (en) 2019-05-10 2022-03-16 GlaxoSmithKline Biologicals S.A. Conjugate production
CN114245746A (zh) 2019-08-05 2022-03-25 葛兰素史克生物有限公司 用于制备包含蛋白d多肽的组合物的方法
BR112021026565A2 (pt) 2019-08-05 2022-05-03 Glaxosmithkline Biologicals Sa Composição imunogênica
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
EP4045150B1 (en) 2019-10-16 2025-11-26 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
PL4021487T3 (pl) 2019-11-15 2024-04-15 Enterome S.A. Peptydy antygenowe do zapobiegania i leczenia nowotworów złośliwych wywodzących się z limfocytów b
US20220387614A1 (en) 2019-11-22 2022-12-08 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
MX2022010355A (es) 2020-02-21 2022-09-21 Pfizer Purificacion de sacaridos.
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
CN111588847B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
JP7630603B2 (ja) 2020-08-10 2025-02-17 インベントプライズ・インコーポレイテッド 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4237428A2 (en) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP2024507828A (ja) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド Ｂ群髄膜炎菌組換えワクチン
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL312890A (en) 2021-11-18 2024-07-01 Matrivax Inc Immunogenic fusion protein compositions and methods of use thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
AU2023246941A1 (en) 2022-03-31 2024-10-24 Enterome S.A. Antigenic peptides for prevention and treatment of cancer.
EP4522208A1 (en) 2022-05-11 2025-03-19 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 成都迈科康生物科技有限公司 一种检测样本中mpl的方法及其相关应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
RU2121481C1 (ru) * 1988-12-16 1998-11-10 Де Стат Дер Недерланден Вертегенвордигд Дор де Министр Ван Велзейн, Волксгезондхейд эн Кюлтюр Модифицированный пневмолизин, рекомбинантная плазмида, способ получения модифицированного пневмолизина, вакцина
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
CA2123580C (en) * 1992-09-16 2005-04-26 James B. Dale Antigen of hybrid m protein and carrier for group a streptococcal vaccine
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
DE69431624T2 (de) 1993-05-18 2003-07-10 The Ohio State University Research Foundation, Columbus Impfstoff gegen mittelohrentzündung
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
AU716806B2 (en) * 1995-04-17 2000-03-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
AU695720B2 (en) 1995-06-07 1998-08-20 Smithkline Beecham Biologicals (Sa) Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
JPH11507214A (ja) 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Ｈｓｐ７０ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
EP0912608B1 (en) 1996-05-01 2006-04-19 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk グレーチング
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
CA2292838A1 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
CA2355364C (en) * 1998-12-21 2014-03-18 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 富士康(昆山)电脑接插件有限公司 线缆连接器组件

Also Published As

Publication number Publication date
LU91652I2 (fr) 2010-10-13
KR100798212B1 (ko) 2008-01-24
AR022964A1 (es) 2002-09-04
US20050031646A1 (en) 2005-02-10
NO20014323D0 (no) 2001-09-05
CN1391481A (zh) 2003-01-15
US20110217329A1 (en) 2011-09-08
CA2366314C (en) 2012-01-10
CZ20013378A3 (cs) 2002-03-13
US8926985B2 (en) 2015-01-06
TWI235064B (en) 2005-07-01
NZ513840A (en) 2004-02-27
CY1107561T1 (el) 2013-03-13
WO2000056358A2 (en) 2000-09-28
IL145045A0 (en) 2002-06-30
BR0009154A (pt) 2001-12-26
WO2000056359A2 (en) 2000-09-28
EP1162999B1 (en) 2006-11-29
EP1163000B1 (en) 2008-02-27
CN1351503A (zh) 2002-05-29
HU229968B1 (hu) 2015-03-30
DE60038166T2 (de) 2009-03-12
HUP0200664A2 (en) 2002-06-29
AU750788B2 (en) 2002-07-25
JP5551579B2 (ja) 2014-07-16
PL204890B1 (pl) 2010-02-26
ATE459373T1 (de) 2010-03-15
NO2011014I1 (no) 2011-09-19
FR10C0008I2 (fr) 2012-10-26
JP2002540074A (ja) 2002-11-26
EP1162998B1 (en) 2010-03-03
NO330532B1 (no) 2011-05-09
JP4846906B2 (ja) 2011-12-28
HUP0200367A2 (en) 2002-05-29
AU3291900A (en) 2000-10-09
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
SI1162999T1 (sl) 2007-04-30
NZ513841A (en) 2001-09-28
IL145044A0 (en) 2002-06-30
JP2002539273A (ja) 2002-11-19
US9168313B2 (en) 2015-10-27
WO2000056358A3 (en) 2001-01-04
CZ301445B6 (cs) 2010-03-03
MY125202A (en) 2006-07-31
US20030147922A1 (en) 2003-08-07
TWI281403B (en) 2007-05-21
PL203917B1 (pl) 2009-11-30
SI1163000T1 (sl) 2008-06-30
JP2002540075A (ja) 2002-11-26
NO330736B1 (no) 2011-06-27
NO20014322L (no) 2001-11-14
DE60043930D1 (de) 2010-04-15
NO20014325D0 (no) 2001-09-05
PL355180A1 (en) 2004-04-05
BRPI0009163B8 (pt) 2021-05-25
KR100642044B1 (ko) 2006-11-10
PL355178A1 (en) 2004-04-05
ES2300255T3 (es) 2008-06-16
CN1351501A (zh) 2002-05-29
ATE346608T1 (de) 2006-12-15
BE1025464I2 (OSRAM) 2019-03-06
US20100119544A1 (en) 2010-05-13
TWI286938B (en) 2007-09-21
HUP0200373A2 (en) 2002-06-29
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
US20060002961A1 (en) 2006-01-05
WO2000056360A3 (en) 2001-01-25
HK1043728A1 (en) 2002-09-27
IL145044A (en) 2007-03-08
HUS1500040I1 (hu) 2018-05-28
CN1191852C (zh) 2005-03-09
BR0009166A (pt) 2001-12-26
HK1043730A1 (zh) 2002-09-27
EP1880735A3 (en) 2008-03-12
NL300415I2 (OSRAM) 2016-12-13
NO20014325L (no) 2001-11-14
AU3430700A (en) 2000-10-09
DK1163000T3 (da) 2008-04-28
HK1043731B (en) 2009-01-23
ATE387214T1 (de) 2008-03-15
FR10C0008I1 (fr) 2010-03-26
CY2009014I2 (el) 2010-07-28
JP2011057713A (ja) 2011-03-24
DE60032120D1 (de) 2007-01-11
DE122009000054I1 (de) 2009-12-31
AU750762B2 (en) 2002-07-25
IL145043A (en) 2007-06-17
CY1107390T1 (el) 2010-07-28
KR20020000549A (ko) 2002-01-05
MXPA01009452A (es) 2002-08-06
CA2366314A1 (en) 2000-09-28
HU228499B1 (en) 2013-03-28
EP1776962A1 (en) 2007-04-25
PL355264A1 (en) 2004-04-05
CN1192798C (zh) 2005-03-16
KR20020000785A (ko) 2002-01-05
AR022963A1 (es) 2002-09-04
TR200102739T2 (tr) 2001-12-21
EP1880735A2 (en) 2008-01-23
NZ513842A (en) 2004-05-28
CZ303653B6 (cs) 2013-01-30
EP2277535A2 (en) 2011-01-26
BRPI0009163B1 (pt) 2019-04-09
NO20014322D0 (no) 2001-09-05
AR022965A1 (es) 2002-09-04
DE60038166D1 (de) 2008-04-10
US20060093626A1 (en) 2006-05-04
EP1163000A2 (en) 2001-12-19
CZ20013379A3 (cs) 2002-03-13
EP2277535A3 (en) 2011-03-09
TR200102736T2 (tr) 2002-04-22
TR200102735T2 (tr) 2002-04-22
IL145043A0 (en) 2002-06-30
PT1162999E (pt) 2007-02-28
BR0009163A (pt) 2001-12-26
DK1162999T3 (da) 2007-03-26
EP1162999A2 (en) 2001-12-19
NO2011014I2 (no) 2011-08-30
EP1162998A2 (en) 2001-12-19
AU3813600A (en) 2000-10-09
ES2339737T3 (es) 2010-05-25
DE60032120T2 (de) 2007-09-20
HK1043731A1 (en) 2002-09-27
AU750913B2 (en) 2002-08-01
WO2000056360A2 (en) 2000-09-28
CY2009014I1 (el) 2010-07-28
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
MY125387A (en) 2006-07-31
KR20020001785A (ko) 2002-01-09
NL300415I1 (nl) 2009-12-01
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
WO2000056359A3 (en) 2001-02-01
LU91652I9 (OSRAM) 2019-01-03
HK1043728B (en) 2007-06-22

Similar Documents

Publication Publication Date Title
CA2366314C (en) Protein d from haemophilus influenzae as a carrier protein in combination vaccines
ZA200107640B (en) Vaccine.
US20150079129A1 (en) Vaccine
HK1106137A (en) Vaccine against streptococcus pneumoniae
HK1114012A (en) Vaccine
MXPA01009459A (es) Vacuna
MXPA01009455A (en) Vaccine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued